187 filings
ARS
2023 FY
SPRO
Spero Therapeutics Inc
16 Apr 24
Annual report to shareholders
4:19pm
DEFA14A
SPRO
Spero Therapeutics Inc
16 Apr 24
Additional proxy soliciting materials
4:15pm
DEF 14A
SPRO
Spero Therapeutics Inc
Definitive proxy
16 Apr 24
4:11pm
8-K
SPRO
Spero Therapeutics Inc
29 Mar 24
Other Events
4:06pm
EFFECT
SPRO
Spero Therapeutics Inc
25 Mar 24
Notice of effectiveness
12:15am
S-8
aof61w 7yrqj
15 Mar 24
Registration of securities for employees
4:18pm
8-K
gmsboidi tzd
13 Mar 24
Spero Therapeutics Announces Fourth Quarter and Full Year 2023
4:07pm
8-K
mm7ojpd
9 Feb 24
Departure of Directors or Certain Officers
4:05pm
8-K
ygciw9neyq i6u0dh8dz
8 Jan 24
Regulation FD Disclosure
6:07am
8-K
vgf9hu86l1y0dme
5 Jan 24
Spero Therapeutics Provides Corporate Update and 2024 Outlook
8:11am
8-K
m2y9giw56lg4e8ggir
2 Jan 24
Spero Therapeutics Announces First Patient First Visit for Phase 3 PIVOT-PO Trial
8:13am
S-8
95cmar0 zxx3jo
13 Nov 23
Registration of securities for employees
4:50pm
S-8
yrfmq5p43lhehi es
13 Nov 23
Registration of securities for employees
4:45pm
8-K
4488o4upw qtuopmo9vi
13 Nov 23
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
4:13pm
8-K
xpmtxp98k59o1y pk
1 Nov 23
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
8:10am
8-K/A
6negtr kh1ezkpvg0
16 Oct 23
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
21px7x5dw6xidihrc04b
10 Oct 23
Departure of Directors or Certain Officers
8:28am